Navigation Links
XYOTAX in Medical News

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results

...operating expenses in 2008, by focusing resources on reaching $15 million in net Zevalin revenues, pursuing European marketing authorization (MAA) for xyotax (paclitaxel poliglumex, CT-2103), preparing for a potential U.S. marketing application (NDA) for pixantrone (BBR 2778) in 2009, and supporting the adv...

Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009

...tates and preparing the marketing applications for xyotax (paclitaxel poliglumex, CT-2103) and pixantrone (B... some phase III clinical trials for pixantrone and xyotax until planned regulatory filings and the completio...uct approvals. CTI expects to file for approval of xyotax in Europe in March. The Company will expand its co...

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

... O'Byrne, M.D., presented the phase III results of xyotax in first-line treatment of non-small cell lung can...." Dr. O'Byrne also presented data suggesting that xyotax may be particularly effective in women with pre-me...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results

...ion of ZEVALIN, coupled with progress on advancing xyotax toward a first half 2008 marketing application sub... phase III clinical trials, PGT307 and PIX303, for xyotax and pixantrone (BBR 2778), respectively. Including...pared to currently marketed anthracyclines. About xyotax XYOTAX(TM) (paclitaxel poliglumex) is a biologica...

Multiple deaths forces cancer trial to be called off

...d in a big way with enrollment made at 170 medical centers globally last April, and had planned to study about 600 patients to prove the efficacy of xyotax in increasing the life span of patients with lung cancer using a regularly used chemotherapy agent coupled with a polymer which is supposed to help in...

Experimental Drug Reduces Tumor Size When Given With Radiation

... An experimental drug xyotax was successful in shrinking stomach and esophagus tumors in four out of 12 cancer patients, according to its maker Cell Therapeutics.// The other pati...
XYOTAX in Medical Technology

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

... beginning of March. The validation of the MAA for xyotax initiates the marketing approval review process, w...of the MAA. In the STELLAR 4 trial, single-agent xyotax resulted in comparable survival to gemcitabine or ...tor support. In addition to improved tolerability, xyotax offered more convenient administration compared to...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)

... xyotax to be reviewed for PS2 first-line non-small cell l...LAR trials. In the STELLAR 4 trial, single-agent xyotax resulted in comparable survival to gemcitabine or ...tor support. In addition to improved tolerability, xyotax offered more convenient administration compared to...

Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill

...atment for lung cancer. Data collected from recent xyotax trials suggests that estrogen levels may alter the...they respond differently to treatment. Through our xyotax studies, we continue to explore ways to turn a neg...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill

...atment for lung cancer. Data collected from recent xyotax trials suggests that estrogen levels may alter the...they respond differently to treatment. Through our xyotax studies, we continue to explore ways to turn a neg...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

...source utilization (MRU) and associated costs with xyotax (paclitaxel polyglumex) treatment compared to gemc... average treatment cost, excluding drug costs, for xyotax patients was nearly half the cost of treatment for...tional, randomized trial (STELLAR 4) that compared xyotax (n=191) to gemcitabine or vinorelbine (n=190) in p...
XYOTAX in Biological Technology

Veteran Drug Industry Executive to Become President of CTI

...ation for FDA approval in late 2008 or early 2009. xyotax is also being studied independently in a phase III... negotiate an exclusive license for pixantrone. If xyotax receives regulatory approval in the U.S. or Europe...ir intended uses, a determination by the EMEA that xyotax should not be approved for sale in Europe, other d...

Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008

...resources to the GOG212 trial, a clinical trial of xyotax in first-line maintenance ovarian cancer being per... in the second half of 2009. The clinical trial of xyotax in combination with carboplatin in women with pre-...for the Company is to focus resources on obtaining xyotax and pixantrone approval with existing or completin...

Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule

...he STELLAR 4 phase III clinical trial results, for xyotax as a single agent for first-line treatment of non-...al The STELLAR 4 phase III clinical trial tested xyotax versus either gemcitabine or vinorelbine for the p...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

... significantly shorter than post-menopausal women. xyotax (TM) (paclitaxel poliglumex) will be studied in co...tion (MAA) in Europe in the first half of 2008 for xyotax as a single agent for first-line treatment of NSCL... 225 patients will be randomized to receive either xyotax 175mg/m2 plus carboplatin (AUC6) or paclitaxel 225...
Other Tags
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid ... Products International and InHealth media is a global sales and communications firm that offers ... pleased to continue our business relationship with Mr. Reid Eckert, as his interpretation of ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... (PRWEB) , ... August 30, 2015 , ... ... Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent ... than a simple digital handwritten signature. , Clinical trial sites can ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... to insufficient scrotal support and protection against dribbled urine and sweat. "In order ... Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the second ... Second quarter contract revenue of $ 85.2 million, ... margins of 26 % , Second quarter ... from royalties in the current quarter , Operating ... pleased to present another strong financial quarter, with all our divisions ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
Other Contents